Overview
X4 Pharmaceuticals Q3 net loss narrows to $29.8 mln from $36.7 mln yr ago
Company raised $240.3 mln in financing, extending cash runway to end of 2028
X4 Pharmaceuticals reports $13 mln annualized cost savings from workforce reduction
Outlook
X4 expects to complete 4WARD trial enrollment by Q3 2026
Company's cash runway extends to end of 2028
X4 plans to launch mavorixafor for chronic neutropenia by end of 2028
Workforce reduction expected to save $13 mln annually
Result Drivers
NET LOSS - Net loss for the three months ended September 30, 2025 was $29.8 million, or $0.69 for basic and diluted loss per share, compared to net loss of $36.7 million, or $5.48 for basic and diluted loss per share, for the same period in 2024
FINANCIAL STRENGTHENING - Raised $240.3 mln in financings, extending cash runway
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.69 | ||
Q3 Net Income | -$29.81 mln | ||
Q3 Income from Operations | -$27.50 mln | ||
Q3 Operating Expenses | $29.27 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $9.00, about 55.9% above its November 4 closing price of $3.97
Press Release: ID:nGNX21sz7z
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)